8 Best Neck Firming Creams To Use in Australia in 2025
These products are hand-picked by our team to help make shopping easier. We may receive payments from third parties for sharing this content and when you purchase through links in this article. Product prices and offer details are not assured, and should be confirmed independently with the retailer. Learn more
Turns out constantly staring at our phones – aka doomscrolling – is not only bad for our minds but also taking a toll on our physical appearance too.
Ever heard of the term 'tech neck'? Well now, you'll never forget it now.
Caused by the forward tilt of your head while continuously looking down at phone and computer screens, 'tech neck' leads to fine lines and creases across the neck that can be very annoying to get rid of.
And no, this isn't about ageing (which, by the way, is a privilege). But if you're looking to soften the appearance of those neck lines, we've rounded up a list of top-rated neck creams that are getting serious buzz.
Keep scrolling for our roundup of the most popular, most-reviewed neck creams you can get your hands on right now – including one from Trinny London that's the beauty entrepreneur's secret to a smoother and firmer neck.
OUR TOP PICKS
The Elevator, $128 at Trinny London
Trinny London The Elevator Neck Cream
Why we love it: It's a highly advanced formula to really target the appearance of fine lines and wrinkles on the delicate neck area.
What to consider: High price tag.
What You Need To Know
The best-selling neck cream from Trinny London is formulated with encapsulated alpha arbutin and a bunch of supercharged peptides to deeply hydrate the skin, brighten its appearance, and visibly soften fine lines for a smoother, plumper-looking neck.
But why does the neck show signs of ageing differently than the face?
We got to hear from Trinny London herself. 'It's because we have fewer things that support it to look younger. Our necks don't have as much fat underneath, which would normally make the skin look plumper. Our neck also doesn't have many sebaceous glands, which means it never gets oily and oiliness can be really good for skin to give it extra hydration,' she explained.
$96 at Adore Beauty
Why we love it: It's a rich, luxurious and creamy texture that feels great to put on.
What to consider: High price tag.
What You Need To Know
Ideal for those with mature, delicate and/or sun damaged skin, the Ella Bache Firming Neck Cream is a super rich treatment that's designed to really hydrate the skin.
It's formulated with a multi-active ingredient called Fabanine, which is a soy plant extract. After continued use, expect to see a more radiant neck area.
Five-star rating Adore Beauty shoppers have said this is a 'very hydrating and rich cream'.
'It has a very luxurious feel when patting in to neck and upper chest area. Wouldn't be without it,' said another happy user.
Why we love it: Universally loved by shoppers for its smooth texture and its results.
What to consider: High price tag.
What You Need To Know
One of Clarins' bestsellers has to be the Super Restorative Decollete and Neck Concentrate. It's packed with skin-loving ingredients like Harungana – something that's unique to the French beauty brand – to really replenish the delicate neck area and make it look more youthful and radiant.
It's racked up a very impressive average rating of 4.9 out of five on the Myer website, with rave reviews from shoppers noting it 'makes a visible difference in a short time'.
'It is a fantastic neck cream that is quickly absorbed and non-greasy,' said another five-star rating customer.
Natio Replenishing Neck and Decolettage Cream
$22.95 at Myer
Why we love it: Super budget-friendly option.
What to consider: May not feel as premium as other neck creams on our list.
What You Need To Know
You don't have to break the bank to get real results from a hardworking neck cream. This one from Natio will cost you under $25 and rave reviews from five-star rating Myer shoppers call it a 'miracle cream', praising it as an 'affordable product that gives results'.
Formulated with collagen-boosting plant peptides and antioxidant-rich bearberry extract, it works to even out skin tone, boost hydration, and leave the neck feeling noticeably softer and smoother.
Why we love it: Over time, this night cream will improve overall radiance of your face and neck.
What to consider: May be too powerful for super sensitive skin types.
What You Need To Know
If you're looking for an overall hardworking night cream that you can use on your face and your neck, this one from RoC Skincare is our top pick.
The formula is led by the ingredient that's had over seven years of research – the Hexyl-R complex – to really help you wake up with a totally renewed and radiant complexion.
Five-star rating iHerb shoppers say this cream 'works really well' and noting it makes a 'big difference' to the overall look of their skin.
Why we love it: This is double-duty day cream for your face and neck.
What to consider: Not suitable to be used at night time.
What You Need To Know
For those of us who want to really simplify our skincare routine, this day cream from No7 is a fabulous option as it combines the function of a cream for your face and neck in one.
Rave reviews from Priceline shoppers say their 'skin feels so much softer and looks brighter both on my face and neck.'
Another five-star reviewer said this is the 'best ever day cream'.
The formula is packed with ginseng extract to revitalise the skin, while antioxidants, peptides and vitamins help to protect the skin.
Finally a hydrating blend of Hibiscus peptides, hyaluronic acid and the brand's signature anti-wrinkle peptide technology is added to really hydrate the skin and help give it a visible glow.
$64 at Adore Beauty
Why we love it: Double-duty product to work for the delicate eye and neck area.
What to consider: High price tag for a small amount of product.
What You Need To Know
Adore Beauty shoppers say this double-duty cream from Skinstitut really works well to give you 'smooth and radiant' skin.
It's formulated with peptides and marine collagen to increase hydration and improve the overall tone and texture of the delicate skin around your eyes and neck.
The beauty brand have also added green coffee extract, avocado oil, aloe vera and ginseng to nourish the skin and give you a more glowy complexion.
The Jojoba Company Neck & Decolletage Lifting Concentrate
$64.95 at Adore Beauty
Why we love it: Offers more of a serum-feel that's super lightweight on the skin.
What to consider: Not a creamy texture like the other options on our list.
Formula: Serum | Size: 30ml | Key ingredient: Powerful botanicals
What You Need To Know
If you're looking for a lightweight treatment that feels more like a serum, rather than a cream, this pick from The Jojoba Company is a standout.
The Neck & Décolletage Lifting Concentrate offers an advanced formula to help boost collagen, replenish and hydrate the skin, and really help encourage a more youthful appearance.
The formula features ingredients specific to Australian beauty brand – Col-Frag 4, Gravityl and Liftylox – which all help to smooth the skin and improve overall radiance.
When choosing neck creams to include in our list, we evaluated several factors:
Price: Neck firming creams can sit at different price points, so you can pay as little as $22.95, with more pricier options sitting at about $155.
Formula: If you want a neck cream to work, it needs to be packed with powerful ingredients – think peptides, retinol, antioxidants and more hydrating, skin-loving actives,
Your skin type: Your skin type can determine what sort of skincare you should use – if you have dry skin, looking for extra hydrating ingredients. For those with sensitive skin, you're going to want to be careful with how many active products you load onto your skin. The skin on our neck can also be more delicate compared to the rest of our face.
HOW WE CHOOSE PRODUCTS
Our team of experienced writers spend hours researching products to include in articles. We find out what factors make a good product by talking to experts, reviewing test results and analysing thousands of customer reviews.
FREQUENTLY ASKED QUESTIONS
WHAT ELSE CAN YOU DO TO FIX TECH NECK?
Besides investing in a neck cream, if you want to keep a smooth and more youthful looking appearance, you're going to want to be applying an SPF every single morning.
The sun's UV rays contribute to all signs of ageing, so keeping your skin protected is key.
Another obvious point is not be on your phone as much – which we know, is not an easy task. Try and take regular breaks, and ensure you maintain good posture while scrolling and having fun with your friends.
WHAT'S THE BEST WAY TO APPLY A NECK CREAM?
For the best results, you should apply your neck cream everyday – think of it as an extension to the rest of your face. Make sure you always follow up with an SPF to keep your skin protected – you can see our roundup of the best ones for your face here.
Sign up to our weekly shopping newsletter to get the best deals, tips and guides delivered straight to your inbox.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
an hour ago
- News.com.au
Modern Family star Julie Bowen thought she was ‘gonna die' after her health diagnosis at 29
Julie Bowen is opening up about her health. The Modern Family star, 55, told Michael Rosenbaum on Tuesday's episode of his Inside of You podcast that she has sick sinus syndrome, a type of rhythm disorder that affects the heart's natural pacemaker, per the Mayo Clinic. Bowen's condition is called hypervagotonia, which is increased activity in the vagus nerve, according to the National Institute of Health. 'I have a low resting heart rate,' she explained, noting that her pacemaker is 'set so that it can't go below 45.' Before the pacemaker, Bowen's resting heart rate was in the 30s, when the 'normal' resting heart rate is between 60 to 100 beats per minute for women. The Hysteria! star's sister diagnosed her condition while the two were on a getaway. Bowen shared that her sibling, Annie Luetkemeyer, had just graduated from medical school and 'was at that time in her life when she, I guess, she always carried around a stethoscope. And we were on vacation, and she was like, 'I wanna listen to this.'' 'She was like, 'That is not what they've been telling you, and it's not runner's heart or whatever. That means you need to go to a cardiologist,'' the Happy Gilmore star remembered. 'I was like, 'I'm fine,'' the actress shared, adding that her sister 'would not let it go.' A month later, Bowen shot the pilot for the NBC series Ed alongside Tom Cavanagh. The comedy/drama ran from 2000 to 2004. 'I shot the pilot of Ed and immediately had to go get a pacemaker afterwards,' Bowen said. 'I was like, 'Oh my God. My life is over. This is so weird. I'm gonna die.' I don't know what I thought it was, because I was 29.' 'You're lucky you didn't die before that,' Rosenbaum, 52, responded. 'They said I wouldn't probably die of it, but I'd start passing out,' Bowen clarified. 'There was a vague feeling … whenever I was relaxed, really relaxed, I'd be, like, watching TV or movie.' The Hubie Halloween star described it felt like she'd 'been holding my breath for a while, that feeling of, like, light-headedness. And they said, 'You're gonna be driving a car, and you're gonna pass out, and you're gonna kill somebody.' And I was like, 'Oh, well, then give me the Goddamn pacemaker.'' Bowen has had the batteries replaced three times; however, she admitted, 'I forget about it all the time.' These days, the Boston Legal star hasn't let her condition slow her down one bit. In fact, she's starring in the upcoming sequel to the beloved 1996 sports comedy Happy Gilmore. Bowen is reprising her role as Virginia Venit, the love interest of Adam Sandler's Happy Gilmore, but didn't know if she'd be asked back for round two. 'I thought, 'Well I won't be in it,'' Bowen told The Hollywood Reporter in June. 'And that was OK — it was like Virginia Venit, it's been 30 years, he's got a hottie. He's got some little bitty on the side, like a cart girl,' she continued. 'As a matter of fact my children told me, before I was even told officially that there was a Happy Gilmore sequel, my now 18-year-old said, 'Mum, I hear they're doing a sequel and he's with Sydney Sweeney as a cart girl.'' Bowen teased, 'I went, I'm hurt and I so respect that move. Of course, why wouldn't you? So when I got the call that I was actually in it, I was like, 'Are you sure? Come on.'' Although Sweeney, 27, isn't in the film, the sequel is set to have a slew of new faces, including Bad Bunny, Margaret Qualley, Benny Safdie, Travis Kelce, Kym Whitley and Eminem. 'Seeing Bad Bunny on set I was just like, 'Oh, I can't actually look you in the eye, I'm going to have to walk away,' and I did,' Bowen recalled. 'I think he was offended and I had to circle back and now I made it worse. I'm the kind of person who doesn't want to meet her heroes because I think I'm just going to be a jackass.'
News.com.au
8 hours ago
- News.com.au
‘Blows my mind': Health battle that led to Aussie man's multimillion-dollar idea
Corbin Halliday was in the midst of a debilitating and terrifying health battle when he came up with a multimillion-dollar idea. When Mr Halliday was 25 years old, his health started unexpectedly failing, and it cost him everything. At the time, Mr Halliday was living in Sydney and working at an acclaimed hair salon when he became so ill that he could no longer work. He suffered from chronic migraines, recurring numbness, extremely high blood pressure, nerve pain and dizzy spells. Mr Halliday went from living his best life to not being able to pay his mortgage because he couldn't work. 'It was such a horrible thing to go through,' he told The hardest part was that he didn't know what was wrong with him. He was in and out of the hospital and was spending days writhing in pain. Finally, he was diagnosed with Chronic Inflammatory Response Syndrome, with doctors determining that it was caused by exposure to black mould that was found inside his home at the time. Mr Halliday was basically bedridden and focusing on recovery when he came up with the idea to create a tanning product without any nasty chemicals. 'My body was so rundown from the mould exposure and anytime I put anything on my body with chemicals, it was making it 10 times worse,' he said. 'I couldn't find anything that was skincare first, self-tan second, that had beautiful ingredients that were organic and cruelty free.' Once Mr Halliday identified the gap in the market, the idea for his tanning company, Three Warriors, wouldn't leave his head. 'I was in and out of the hospital and I was so unwell. I was so dizzy and I was in tears all the time and starting to research about tanning was such a good distraction,' he explained. Mr Halliday came up with the formula in his kitchen alongside a friend, a biochemist, and then he was able to turn his idea into a reality. However, he still needed help getting it off the ground. At this point, his health struggles had left him in a dire financial situation, which meant he couldn't afford to pay his mortgage, let alone fund a business venture. 'My mum believed in me,' he said. Mr Halliday's mum she supported him, not just by lending him $10,000 to start the brand, but also by paying his mortgage and attending every one of his doctor's appointment. 'She did everything for me. My family were so supportive,' he said. In the end, his mum loaned him an extra $50,000 so he could place the first order for his tanning product after he felt the formula was perfected. It was a slow burn, but now, seven years later, the brand's gradual tan product sells every 30 seconds. The tanning brand is also stocked in big chains like David Jones in Australia and internationally in Harrods. It also has a slew of celebrity fans, including Sonia Kruger, who serves as a brand ambassador, as well as celebrities like Daisy Edger Jones, LeAnn Rimes, and Matt Bomer. It's been a dream come true. 'It still blows my mind,' he said. 'The first couple of years the business was ticking along and now we are selling gradual tan every 30 seconds.' The gradual tanning product in particular has become so successful that it is now impossible to keep up with demand. 'We can't keep it in stock. Every year it sells out in Australia. It just goes bang and sells out' he said. The tanning king said in the last three years, and since he has launched his e-commerce business, the brand has sold over $200,000 units of just that product alone and made $6.5 million in sales. As for his health, it is still a work in progress, but he can now at least afford any treatment he needs. 'If you've been exposed for six years it can take up to 10 years to recover. I started getting sick when I was 25 and now I'm now 38 and I've only started to feel better a few years ago,' he said. 'I still have flair ups.' Running his own business, though, and building something from scratch has helped him get through rough patches with his health. 'It honestly saved me,' he said. The now 38-year-old is so proud of what the brand has achieved over the last seven years and also can't wait to do more. 'You never think in your life you're going to do this,' he said.
News.com.au
9 hours ago
- News.com.au
Biocurious: Dimerix could be riding big and beautiful kidney drug success earlier than expected
With the FDA's blessing, Dimerix will use phase III trial endpoints that could lead to accelerated approval for its kidney disease drug Dimerix is confident of phase III success because an expert 'peek' at the blinded data shows it's on the right track The company is well cashed up, courtesy of four global distribution deals When it comes to clinical trials, the choice of primary endpoints can mean the difference between a trial failing and a billion-dollar blockbuster drug emerging. Plenty of drug candidates have looked successful at mid stage, but then floundered because a later stage trial has failed to meet strictly defined goals. This appears to be the case with Opthea (ASX:OPT) and the recent failure of its two phase III eye disease trials. In other cases, strictly enforced endpoints mean that a trial is too long and too expensive. But regulatory attitudes are changing. In the case of Dimerix (ASX:DXB), the US Food & Drug Administration (FDA) has delivered the kidney disease drug developer a concession on endpoints for its ongoing phase III trial. The FDA's stance not only means that the endpoints are more likely to be achieved, reducing risk. It also means the company could win accelerated FDA marketing approval before the study has completed. 'That sparked a lot of interest in the sector because suddenly the trials are more manageable,' says Dimerix chief Dr Nina Webster. The 286-patient study is testing Dimerix's candidate DMX-200 for the regressive focal segmental glomerulosclerosis (FSGS). A rare – but not ultra rare – disease, FSGS usually results in end-stage kidney failure. Endpoints have delayed the endgame Previously, the FDA had set an endpoint of how well a drug preserves kidney function. But this meant a trial had to track the patient to kidney failure or death, which could take years. This makes a trial too long and too costly. 'In rare diseases, no-one is going to do these studies,' Webster says. About five years ago the FDA became more amenable to the use of 'surrogate' endpoints These are measures that substitute a true clinical endpoint to expedite drug development. The FDA allowed the use of the kidney function biomarker, called estimated global filtration rate (eGFR). Under the dainty banner of 'Parasol' – and, no it's not an umbrella group – experts advised the use of proteinuria as a further alternative endpoint for FSGS. Proteinuria is kidney proteins seeping into the urine, while eGFR is the rate at which the spuds can cleanse blood. If proteinuria is present and the eGFR is not up to scratch, they are sure signs the kidneys are not working as they should. Conversely, if a drug reduces proteinuria or the eGFR 'slope rate' – the rate of decline – it is accepted as being effective. Parasol promises faster Action Dubbed Action 3, the Dimerix trial involves two years' treatment, as measured against placebo. The study is due to complete in 2027 when the last patients have been treated. But Dimerix now is working with Parasol to establish the exact surrogate endpoints required to front the FDA for accelerated marketing approval. Expedited approval is as allowed for some orphan drugs, such as DMX-200. 'The full study is for two years and that doesn't change,' Webster says. 'Th question is whether we can get interim approval and go to market earlier.' One possibility is that proteinuria alone could be the accepted endpoint, given proteinuria and eGFR appear to point to the same thing. That is: deteriorating kidneys. Dr Webster says an accelerated endpoint must reasonably predict the outcome of the trial. 'The question is, what do we need to see at point X to prove the end at point Y? Parasol is working with us on that. 'We're collecting all of our data on eGFR and proteinuria anyway, so it gives us a lot of flexibility in the program.' (Other geographies such as Japan and Europe still require an eGFR endpoint). Surrogate change spurs others … The FDA's stance on surrogate endpoints could be a double-edged sword for Dimerix, as it also provides succour to potential rivals. In this vein, a drug called sparsentan (brand name Filspari ) won FDA approval for a kidney condition called IgA nephropathy. The drug failed its Phase III endpoint for eGFR. But now its owner Travere Therapeutics is having a crack at FDA marketing approval for FSGS using a proteinuria endpoint. The data from the supportive trial was unblinded, which means the study custodians can't change the endpoints retrospectively. 'But the FDA is in a hard spot with this one because is an area of such high unmet need,' Webster says. 'These patients currently have limited treatment options and Filspari looks like it is doing something for them. 'We are waiting with bated breath in the hope that Filspari is approved and gives hope to these patients.' Travere has licensed the European and local sparsentan rights to our own CSL (ASX:CSL). … but we're friends, not rivals Webster says rather than rivalling DMX-200, sparsentan could be used in unison. An angiotensin receptor, sparsentan targets high blood pressure – a key cause of kidney disease in the first place. (High blood pressure causes inflammation which causes scarring and cell death). Thus, sparsentan needs to be better than the current blood pressure medication. But DMX-200 works on the secondary inflammatory pathway, with the patients already on blood pressure meds. 'It's not apples for apples with study design, which is why we are compared against the placebo and not a comparator,' Webster says. In effect, DMX-200 faces a lower comparative hurdle. 'Our drug is complementary, not competitive,' Webster says. Data 'peek' hints at trial success While a trial result is never certain, Dimerix is confident it won't meet the fate of Opthea or Percheron Therapeutics (ASX:PER). (The latter's neurological disease trial also failed to meet primary endpoints). One reason is that the Action 3 trial already has been subject to a blinded interim analysis by an arm's length expert committee, which peeked at the data. 'Blinded' means that Dimerix, the trial investigators and the patients don't know the results. In March last year the 72-patient analysis reported that DMX-200 worked better than placebo. As per protocol, the experts did not disclose the extent of this efficacy. But it was enough for the company to know that it's on the right track. 'We just know at that point in time, we were doing better and that if we carry on that trajectory, we have a shot at the endpoint,' Webster says. 'That was a big moment for us, because we wanted to confirm something similar to our smaller phase II study in a larger cohort of patients.' FDA approval could come sooner rather than later Dimerix has received over $65 million of cash, courtesy of four distribution deals that may deliver up to $1.4 billion of milestone payments plus royalties. While a further capital raising is a case of 'never say never', it's unlikely. Naturally, most of the milestones are back ended to achievements such as phase III success and FDA approval. But with accelerated approval possible after the interim analysis, the latter might be sooner than investors think. Many drug developers view the Trump Ascendancy Mark Two with trepidation. In contrast, Webster notes Trump nominated kidney disease as a key health priority in his first stab at POTUS. The financial motive alone is compelling, in that dialysis costs the US health system around US$125 billion annually. 'We are in the sweet spot of being a rare disease (with pricing benefits) and having the potential to reduce US healthcare costs,' Webster says.
